Cognitive therapy for sickle cell disease (SCD) pain

Submission date 23/01/2004	Recruitment status No longer recruiting
Registration date 23/01/2004	Overall study status Completed
Last Edited 25/07/2011	Condition category Haematological Disorders

[] Prospectively registered

[] Protocol

[] Statistical analysis plan

[X] Results

[] Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s) Scientific

Contact name Dr Veronica Thomas

Contact details

King's College London University of London Department of Nursing Cornwall House Waterloo Road London United Kingdom SE1 8WA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers REC00056

Study information

Scientific Title

Study objectives

Painful crises are the most common manifestation of sickle cell disease and accounts for the greatest number of admissions with an average length of stay of seven days. This causes severe disruption to the educational and social aspects of life for these patients. The financial implications for the health service are also considerable. A recent analysis revealed a cost of £2.5 million per annum for South East London Health Authority. Research conducted in America revealed that pain management strategies that incorporate a psychological intervention can significantly reduce casualty visits and hospital admissions. A pilot study using cognitive therapy has been carried out to assess the feasibility of using this approach in patients with Sickle Cell Disease in London. Results have shown that patients are generally very positive about this approach and consider it to be beneficial in terms of reducing psychological distress, providing emotional support and in improving confidence levels. There was a significant reduction in the duration of hospital stay when compared to the control group.

The present study seeks to extend the pilot study by evaluating of a community-based cognitive therapy intervention of the pain experience and well-being of 120 adolescents and young adults with sickle cell disease. The result of this study is likely to make significant contributions to knowledge by providing detailed information about the types of coping strategies used by patients with SCD. In addition information gained will enable us to determine whether the proposed intervention is cost effective and beneficial to a group of patients whose pain is notoriously difficult to manage.

Ethics approval required

Old ethics approval format

Ethics approval(s) Not provided at time of registration

Study design Randomised controlled trial

Primary study design Interventional

Secondary study design Randomised controlled trial

Study setting(s) Not specified

Study type(s) Not Specified

Participant information sheet

Health condition(s) or problem(s) studied

Sickle cell anaemia

Interventions

A cognitive behavioural therapy pain management group
 An attention placebo group
 Non-intervention control group

Intervention Type

Other

Phase Not Specified

Primary outcome measure

Patient self-assessments: GHQ 30, Coping Strategies Questionnaire (CSQ), Pain Self Efficacy Questionnaire, Short Form McGill Pain Questionnaire

Secondary outcome measures

Not provided at time of registration

Overall study start date 31/12/1996

Completion date 31/12/1998

Eligibility

Key inclusion criteria

Male and female SCD patients with the SS genotype between 15 and 26 years of age, who have had three or more admissions in the previous calendar year.

Participant type(s) Patient

Age group Not Specified

Sex Both

Target number of participants Not provided at time of registration

Key exclusion criteria Not provided at time of registration

Date of first enrolment 31/12/1996

Date of final enrolment 31/12/1998

Locations

Countries of recruitment England

United Kingdom

Study participating centre King's College London London United Kingdom SE1 8WA

Sponsor information

Organisation NHS R&D Regional Programme Register - Department of Health (UK)

Sponsor details

The Department of Health Richmond House 79 Whitehall London United Kingdom SW1A 2NL +44 (0)20 7307 2622 dhmail@doh.gsi.org.uk

Sponsor type

Government

Website http://www.doh.gov.uk

Funder(s)

Funder type Government **Funder Name** NHS Executive London (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/02/2001		Yes	No